Non-nucleoside reverse transcriptase inhibitors
    2.
    发明授权
    Non-nucleoside reverse transcriptase inhibitors 有权
    非核苷逆转录酶抑制剂

    公开(公告)号:US07208509B2

    公开(公告)日:2007-04-24

    申请号:US10807766

    申请日:2004-03-23

    摘要: This invention relates to novel heterocyclic compounds of formula I wherein R1—R4, X1 and X2 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I, pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient and processes to prepare compounds of formula I. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated

    摘要翻译: 本发明涉及式I的新型杂环化合物,其中R 1,R 2,R 4,X 1和X 2, 在其总结及其药学上可接受的盐和溶剂合物中定义,用式I化合物抑制或调节人类免疫缺陷病毒(HIV)逆转录酶的方法,含有式I的药物组合物与至少一种溶剂,载体或赋形剂混合, 制备式I化合物的方法。该化合物可用于治疗涉及HIV和遗传相关病毒的疾病

    Nonnucleoside reverse transcriptase inhibitors
    4.
    发明授权
    Nonnucleoside reverse transcriptase inhibitors 失效
    非核苷逆转录酶抑制剂

    公开(公告)号:US07241794B2

    公开(公告)日:2007-07-10

    申请号:US10781373

    申请日:2004-02-18

    IPC分类号: A61K31/415 C07D231/18

    摘要: This invention relates to novel pyrazole derivatives of formula I wherein R1 to R4 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I and pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated

    摘要翻译: 本发明涉及式I的新型吡唑衍生物,其中R 1至R 4如概述中所定义及其药学上可接受的盐和溶剂合物,用式I化合物抑制或调节人类免疫缺陷病毒(HIV)逆转录酶的方法和含有 式I与至少一种溶剂,载体或赋形剂混合。 该化合物可用于治疗涉及HIV和遗传相关病毒的疾病

    Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases
    5.
    发明申请
    Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases 审中-公开
    哌啶衍生物用于治疗趋化因子受体5介导的疾病

    公开(公告)号:US20100099708A1

    公开(公告)日:2010-04-22

    申请号:US12518489

    申请日:2007-12-10

    CPC分类号: C07D401/14

    摘要: The present invention relates to 4-[3-(1,1-difluoroethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-1-{(1R,3R)-3-(3,5-difluorophenyl)-1-methyl-3-[1-(methylsulfonyl)ρiperidin-4-yl]propyl}piperidine formula (I): or a pharmaceutically acceptable salt thereof, as well as processes for the preparation of this compound and its use in the treatment of CCR5 disease states.

    摘要翻译: 本发明涉及4- [3-(1,1-二氟乙基)-5-甲基-4H-1,2,4-三唑-4-基] -1 - {(1R,3R)-3-(3 ,5-二氟苯基)-1-甲基-3- [1-(甲基磺酰基)哌嗪-4-基]丙基}哌啶式(I):或其药学上可接受的盐,以及其制备方法 化合物及其用于治疗CCR5疾病状态。

    HIV protease inhibitors
    7.
    发明授权
    HIV protease inhibitors 失效
    HIV蛋白酶抑制剂

    公开(公告)号:US06472404B1

    公开(公告)日:2002-10-29

    申请号:US09999082

    申请日:2001-11-20

    IPC分类号: A61K31472

    摘要: The present invention discloses novel isoquinoline carboxamide derivatives which are HIV protease inhibitors or prodrugs thereof, a process for their manufacture, pharmaceutical compositions and the use of such compounds in medicine. In particular, the compounds are hydroxyethylamine tripeptide mimetics which act as inhibitors of the HIV aspartyl protease, an essential enzyme in the replicative life cycle of HIV. Consequently, the compounds of this invention may be advantageously used in the treatment of HIV infection, either alone or in combination with other inhibitors of HIV viral replication or with pharmacoenhancers such as cytochrome P450 inhibitors.

    摘要翻译: 本发明公开了新型异喹啉羧酰胺衍生物,它们是HIV蛋白酶抑制剂或其前体药物,其制备方法,药物组合物和这些化合物在医药中的用途。 特别地,这些化合物是作为HIV天冬氨酰蛋白酶抑制剂的羟乙基胺三肽模拟物,HIV复制生命周期中必不可少的酶。 因此,本发明的化合物可以单独使用或与HIV病毒复制的其它抑制剂组合或与诸如细胞色素P450抑制剂的药物化合物一起有利地用于治疗HIV感染。

    Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases
    8.
    发明申请
    Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases 审中-公开
    哌啶衍生物用于治疗趋化因子受体5介导的疾病

    公开(公告)号:US20100093795A1

    公开(公告)日:2010-04-15

    申请号:US12518504

    申请日:2007-12-10

    IPC分类号: A61K31/4545 C07D401/14

    CPC分类号: C07D401/14

    摘要: The present invention relates to 4-{(1R,3R)-1-(3,5-difluorophenyl)-3-[4-(3-ethyl-5-isopropyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl]butyl}-1-(methylsulfonyl)piperidine formula (I): or a pharmaceutically acceptable salt thereof, as well as to processes for preparing such a compound, to pharmaceutical compositions comprising such a compound and to the use of such a compound in the treatment of CCR5 mediated disease states.

    摘要翻译: 本发明涉及4 - {(1R,3R)-1-(3,5-二氟苯基)-3- [4-(3-乙基-5-异丙基-4H-1,2,4-三唑-4-基) 吡啶-2-基)哌啶-1-基]丁基} -1-(甲基磺酰基)哌啶式(I):或其药学上可接受的盐,以及制备这种化合物的方法,包含这种化合物的药物组合物和 使用这种化合物治疗CCR5介导的疾病状态。

    Chemical Compound
    9.
    发明申请
    Chemical Compound 审中-公开
    化合物

    公开(公告)号:US20080139613A1

    公开(公告)日:2008-06-12

    申请号:US11953205

    申请日:2007-12-10

    CPC分类号: C07D401/14

    摘要: The present invention relates to 4-{(1R,3R)-1-(3,5-difluorophenyl)-3-[4-(3-ethyl-5-isopropyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl]butyl}-1-(methylsulfonyl)piperidine (I): or a pharmaceutically acceptable salt thereof, as well as to processes for preparing such a compound, to pharmaceutical compositions comprising such a compound and to the use of such a compound in the treatment of CCR5 mediated disease states.

    摘要翻译: 本发明涉及4 - {(1R,3R)-1-(3,5-二氟苯基)-3- [4-(3-乙基-5-异丙基-4H-1,2,4-三唑-4-基) 吡啶-1-基)哌啶-1-基]丁基} -1-(甲基磺酰基)哌啶(I):或其药学上可接受的盐,以及制备这种化合物的方法,包含这种化合物的药物组合物和使用 的这种化合物在治疗CCR5介导的疾病状态。

    Chemical Compound
    10.
    发明申请
    Chemical Compound 审中-公开
    化合物

    公开(公告)号:US20080139612A1

    公开(公告)日:2008-06-12

    申请号:US11953197

    申请日:2007-12-10

    CPC分类号: C07D401/14

    摘要: The present invention relates to 4-[3-(1,1-difluoroethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-1-{(1R,3R)-3-(3,5-difluorophenyl)-1-methyl-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidine (I): or a pharmaceutically acceptable salt thereof, as well as processes for the preparation of this compound and its use in the treatment of CCR5 disease states.

    摘要翻译: 本发明涉及4- [3-(1,1-二氟乙基)-5-甲基-4H-1,2,4-三唑-4-基] -1 - {(1R,3R)-3-(3 ,5-二氟苯基)-1-甲基-3- [1-(甲基磺酰基)哌啶-4-基]丙基}哌啶(I):或其药学上可接受的盐,以及该化合物及其制备方法 用于治疗CCR5疾病状态。